Rita Nanda, MD, The University of Chicago Medicine

Articles

HER2-Negative and HER2-Low mBC: Key Takeaways

July 28th 2025

Panelists discuss how the field has made exciting strides, with oral selective estrogen receptor degraders (SERDs) likely moving into early-stage disease and the need for alternative antibody-drug conjugate (ADC) payloads beyond topoisomerase I inhibitors to overcome resistance mechanisms.

Defining HER2-Low and -Ultralow Expression: Practical Challenges and Solutions

July 28th 2025

Panelists discuss how HER2 testing challenges for identifying HER2-low and -ultralow expression require coordination with pathologists and may involve

Sequencing ADCs in HER2-Low and -Ultralow mBC: Clinical Considerations and Emerging Evidence

July 21st 2025

Panelists discuss how they approach sequencing decisions for patients with hormone receptor–positive, HER2- low/ultralow disease, emphasizing selective use of trastuzumab deruxtecan in first-line chemotherapy settings while considering quality-of-life factors.

DESTINY-Breast06: Updates From Subgroup and Biomarker Analyses

July 21st 2025

Panelists discuss how subgroup analyses from DESTINY-Breast06 show trastuzumab deruxtecan benefits across different mutation groups, with particularly strong responses in patients with BRCA1/2-mutated disease due to the topoisomerase I inhibitor payload.

Navigating Treatment Selection for HER2-Low and -Ultralow Metastatic Breast Cancer

July 14th 2025

Panelists discuss how treatment options for HER2-low and HER2-ultralow metastatic breast cancer include trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan, with sequencing becoming a key consideration.

Balancing Efficacy and Safety of ADCs in HER2– Metastatic Breast Cancer

July 14th 2025

Panelists discuss how to manage toxicities associated with datopotamab deruxtecan, particularly ocular toxicity and stomatitis, using prophylactic measures such as steroid mouthwash and eye drops.

Evolving ADC Strategies in HER2– mBC: TROPION-Breast01 and Real-World Data From ASCO 2025

July 7th 2025

Panelists discuss how datopotamab deruxtecan from the TROPHY-PD-01 trial compares with sacituzumab govitecan, highlighting different toxicity profiles and the challenge of sequencing multiple antibody-drug conjugates (ADCs) with the same TROP2 payload.

TROPiCS-02 Trial: Sacituzumab Govitecan in HR+/HER2– Breast Cancer

July 7th 2025

Panelists discuss how the TROPiCS-02 trial established sacituzumab govitecan for hormone receptor–positive, HER2-negative metastatic breast cancer and how it influences sequencing decisions with other antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan.

When to Introduce ADCs in HR+/HER2– mBC

June 30th 2025

Panelists discuss how they decide when to transition from endocrine-based therapies to antibody-drug conjugates, considering factors such as endocrine sensitivity, disease burden, and pace of progression.

Optimizing Treatment Selection and Sequencing in HR+/HER2– mBC

June 30th 2025

Panelists discuss how to approach decision-making among PI3K/AKT pathway inhibitors (capivasertib, alpelisib, everolimus) based on mutation status, toxicity profiles, and dosing schedules in the second-line setting.

Efficacy and Safety of Next-Generation Oral SERDs for HR+/HER2– mBC

June 23rd 2025

Panelists discuss how upcoming oral selective estrogen receptor degraders (SERDs; eg, camasertinib, imlunestrant, and giredestrant) are showing efficacy primarily in populations with ESR1 mutations and are all well-tolerated oral agents that will likely receive approvals.

The Role of Elacestrant in the Treatment of ER+/HER2– mBC

June 23rd 2025

Panelists discuss how elacestrant from the EMERALD trial is being incorporated into practice based on ESR1 mutation status and duration of prior CDK4/6 inhibitor therapy, with combination approaches being explored in the ELEVATE trial.

Camizestrant in HR+/HER2– mBC: Emerging Data From the SERENA-6 Trial

June 16th 2025

Panelists discuss how the SERENA-6 trial design uses circulating tumor DNA (ctDNA) monitoring to detect ESR1 mutations and switch patients from aromatase inhibitors to oral selective estrogen receptor degraders (SERDs) such as camasertinib while continuing CDK4/6 inhibitors.

Biomarker Testing Strategies in Metastatic Breast Cancer

June 16th 2025

Panelists discuss how they will review the latest updates in hormone receptor–positive, HER2-negative, and HER2-low metastatic breast cancer, focusing on oral selective estrogen receptor degraders (SERDs), targeted therapies, and antibody-drug conjugates presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

Dr Nanda on Neoadjuvant Treatment in HER2+ Breast Cancer

April 4th 2024

Rita Nanda, MD, discusses the future of neoadjuvant treatment for patients with HER2-positive breast cancer.

Therapeutic Advances in Prophylaxis Against CIN

December 3rd 2021

An overview of therapies used as prophylaxis against chemotherapy-induced neutropenia and projections on improving quality of life for patients with solid tumors with therapeutic advances.

CIN: Adopting SIMBA Therapy Into Clinical Practice

December 3rd 2021

A panel of oncologists react to their interest in using plinabulin as prophylaxis against chemotherapy-induced neutropenia in future clinical practice.

CIN: Implications of the PROTECTIVE-2 Study

November 29th 2021

Implications for treating patients with solid tumor cancers with plinabulin based on quality-of-life data and results demonstrated by the PROTECTIVE-2 trial.

CIN: Takeaways From the PROTECTIVE-1 Study

November 12th 2021

An overview of the design and results of the PROTECTIVE-1 study of plinabulin versus pegfilgrastim in patients with solid tumors receiving docetaxel myelosuppressive chemotherapy.

CIN Treatment Advances: SIMBA Therapy

November 12th 2021

What to know about plinabulin, a first-in-class selective immunomodulating microtubule-binding agent (SIMBA), in preventing chemotherapy-induced neutropenia.